Insider · CIK 0001834423
John S. Montalbano
Files at ABCL (AbCellera Biologics Inc.). First filing Mar 7, 2025, latest Aug 18, 2026.
John S. Montalbano files SEC Form 4 as director at ABCL (AbCellera Biologics Inc.). Since Mar 7, 2025, John S. Montalbano has reported 5 open-market buys worth $582k and 0 open-market sells worth $0, the latest filed on Aug 18, 2026.
After John S. Montalbano's past buys, the stock beat the S&P 500 by a median 68.1% over six months (n = 3), and 100% of those buys were ahead of the index at six months. InsiderTell labels that a strong record.
The newest scored trade: bought $110k of ABCL on Aug 18, 2026, filed Aug 18, 2026, scored 50 (moderate). In the last 12 months: 3 buys worth $384k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ABCL: AbCellera Biologics Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | AbCellera Biologics Inc. | $110k 10,000 shares | +4% | +300% from low-2% from high | |
| 32Weak | ABCLbuy AbCellera Biologics Inc. | $95k 20,000 shares | +9% | +123% from low-29% from high | |
| 41Moderate | ABCLbuy AbCellera Biologics Inc. | $178k 50,000 shares | +29% | +89% from low-41% from high | |
| 38Weak | AbCellera Biologics Inc. | $58k 25,000 shares | +17% | - | |
| 44Moderate | AbCellera Biologics Inc. | $141k 60,000 shares | +70% | - |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | ABCL AbCellera Biologics Inc. | POpen-market purchase Common Shares | +10,000 | $11.03 | $110k | 251,000 | Aug 18, 2026 |
| Jun 11, 2026 | ABCL AbCellera Biologics Inc. | AGrant or award Share option (right to buy)derivative | +111,701 | $0.00 | $0 | 1,141,544 | Jun 12, 2026 |
| May 14, 2026 | ABCL AbCellera Biologics Inc. | POpen-market purchase Common Shares | +20,000 | $4.77 | $95k | 241,000 | May 18, 2026 |
| Nov 26, 2025 | ABCL AbCellera Biologics Inc. | POpen-market purchase Common Shares | +50,000 | $3.57 | $178k | 221,000 | Nov 26, 2025 |
| Jun 12, 2025 | ABCL AbCellera Biologics Inc. | AGrant or award Share option (right to buy)derivative | +238,864 | $0.00 | $0 | 1,029,843 | Jun 16, 2025 |
| Mar 10, 2025 | ABCL AbCellera Biologics Inc. | POpen-market purchase Common Shares | +25,000 | $2.30 | $58k | 171,000 | Mar 10, 2025 |
| Mar 6, 2025 | ABCL AbCellera Biologics Inc. | POpen-market purchase Common Shares | +60,000 | $2.34 | $141k | 146,000 | Mar 7, 2025 |
Questions about John S. Montalbano
Answered from the filings on this page, as of the latest one.
Is John S. Montalbano buying or selling?
In the last 12 months John S. Montalbano reported 3 open-market buys worth $384k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $110k of ABCL on Aug 18, 2026. Grants, option exercises and tax withholding are not counted.
How did John S. Montalbano's past buys perform?
Measured from the first close after each filing, the stock beat the S&P 500 by a median 68.1% over six months across 3 past buys, with 100% ahead of the index. Past results describe what happened; they do not predict the next trade.
Where does John S. Montalbano file Form 4?
John S. Montalbano has filed Form 4 at ABCL (AbCellera Biologics Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.